

November 11, 2022

**Consolidated Financial Results for
the Second Quarter of the Year Ending in
March 31, 2023 (FY2022)**

Presentation for Investors



Stock code : 4886 (TSE)

ASKA Pharmaceutical Holdings Co., Ltd.

Forward Looking Statement

- The forward-looking statements contained in this presentation are based on the Company's assumptions and beliefs in the light of information currently available to it and involves known and unknown risks and uncertainties.
- Accordingly, there is a possibility that actual results and development programs may differ largely from these forecasts, due to a variety of factors.
- This report contains information on Pharmaceuticals Products (including those under development), and the content of this report is not intended for medical promotion or medical advice.
- This translation is provided solely as a reference material. In the case of any discrepancy between the two versions, the original Japanese version shall prevail.

Financial Results Summary for 2Q FY2022



Atsushi Maruo,

Senior Managing Member of the Board of Directors, Representative Director

ASKA Pharmaceutical Holdings Co., Ltd.

Highlight of Financial Results Summary for 2Q FY2022

Net sales (Consolidated)

✓ **rose 6.0% YOY to a record high of 30.1 billion yen**

A record high of net sales driven by expansion of pharmaceutical and animal health businesses

Cost of sales

✓ **was 15.8 billion yen, ratio of cost of sales to net sales improved 0.3 points YOY**

Product mix improved due to growth in sales of brand-name drugs such as RELUMINA, THYRADIN, and RIFXIMA

SG&A expenses

✓ **rose 6.1% YOY to 11.4 billion yen**

SG&A expenses was impacted by an increase in business activity expenses due to the gradual return in social and economic activities

Full year forecast

✓ **upwardly revised**

We upwardly revised net sales, operating profit, ordinary profit, and profit attributable to owners of parent for FY2022 forecast

Consolidated Statements of Income

(Millions of yen)	FY2021 Apr - Sep Actual	FY2022 Apr - Sep Actual	Actual +/-	Growth +/-
Net sales	28,477	30,172	1,694	6.0%
Cost of sales	15,051	15,870	819	5.4%
Gross profit	13,426	14,301	875	6.5%
Selling, general and administrative expenses	10,768	11,422	653	6.1%
Operating profit	2,657	2,879	221	8.3%
Ordinary profit	2,743	2,987	244	8.9%
Profit attributable to owners of parent	- 2,796	2,346	5,143	

* Put a current exchange rate and the reference: (1 US dollar = 146.62 yen, as of November 7th 2022)
(1 Euro = 146.90 yen, as of November 7th 2022)

Consolidated Net Sales by Business

(Millions of yen)	FY2021 Apr - Sep Actual	FY2022 Apr - Sep Actual	Breakdown	Actual +/-	Growth +/-
Pharmaceutical business	25,619	26,851	89.0%	1,231	4.8%
Animal health business	2,791	3,234	10.7%	443	15.9%
Other businesses	66	86	0.3%	19	29.7%
Total	28,477	30,172	100%	1,694	6.0%

Sales of Main Products

(Millions of yen)

Area	Category	Products (generic name)	FY2021	FY2022 Apr - Sep		FY2022		Reference	Notes
			Actual	Actual	YOY		YOY	Previous Forecast	
Internal Medicine	Generic (AG)	CANDESARTAN ^{*1} (candesartan)	6,259	5,477	87.5%	10,697	86.3%	10,840	The NHI drug price has decreased, but sales on a quantity basis have been maintained.
	Brand-name	THYRADIN (levothyroxine)	3,790	3,921	103.5%	7,706	102.8%	7,714	July 2022:100th anniversary of the brand
	Brand-name	RIFXIMA (rifaximin)	2,464	2,757	111.9%	5,500	113.3%	5,289	
	Brand-name	MERCAZOLE (thiamazole)	751	761	101.4%	1,467	100.6%	1,440	
	Generic	AMLODIPINE (amlodipine)	555	465	83.8%	937	87.3%	963	
Obstetrics and Gynecology	Brand-name	RELUMINA (relugolix)	3,703	4,524	122.2%	9,671	131.9%	9,779	December 2021: Additional indication for endometriosis
	Generic (AG)	FREWELL (norethisterone/ethinylestradiol)	1,667	1,765	105.9%	3,276	94.6%	3,083	The NHI drug price declined, but sales increased due to market expansion
	Generic	DroEthi (drospirenone/ethinylestradiol)		1,279		3,023		1,944	June 2022: Only ASKA launched
	Brand-name	ANGE (levonorgestrel/ethinylestradiol)	446	420	94.2%	859	100.5%	896	
	Brand-name	LUTEUM (progesterone)	298	569	190.6%	979	148.1%	836	April 2022: Insurance coverage for infertility treatment has been commenced
	Brand-name	MAGSENT ^{*2} (magnesium sulfate)	467	309	66.2%	644	75.7%	682	Return to the premium for new drug innovation
Urology	Generic	LEUPRORELIN ^{*3} (leuprorelin)	2,520	2,619	103.9%	5,018	96.8%	4,589	

* 1 Including compounding agents


* 2 Total value of magnesium sulfate preparation

* 3 1.88mg formulation is for gynecological indications only, but combined with 3.75mg formulation



Analysis of Operating Profit (YOY)

(Millions of yen)




Analysis of key factors

- ❑ While gross profit increased due to increase in revenue, expenses in business operations increased since the influence of COVID-19 is in a lull.
- ❑ Depreciation increased due to amortization of sales rights.
- ❑ R&D expenses decreased because some R&D expenses were not recorded within the appropriate quarter.

Consolidated Balance Sheet

End of FY2021


(Millions of yen)



Total assets 83,297 million yen

End of 2Q FY2022

(Millions of yen)



Total assets 86,227 million yen(+2,929)

Analysis of key factors

Assets

Notes and accounts receivable - trade, and contract assets	+1,876
Raw materials and supplies	+1,191
Intangible assets	-990

Liabilities・Net assets

Notes and accounts payable – trade	+1,180
Electronically recorded obligations – operating	-1,208
Short/Long-term borrowings	-1,149
Retained earnings	+2,120

FY2022 Forecast (Consolidated)

(Millions of yen)	FY2021 Actual	FY2022 Previous Forecast	FY2022 Revised Forecast	YOY Actual +/-	YOY % +/-
Net sales	56,607	57,500	60,000	3,392	6.0%
Operating profit	4,795	4,200	5,200	404	8.4%
Ordinary profit	4,880	4,300	5,300	419	8.6%
Profit attributable to owners of parent	4,290	3,300	4,200	-90	-2.1%


Major factors

- Net sales are projected to exceed the figures previously announced as a result of strong sales of obstetrics and gynecology product groups in the pharmaceutical business and steady sales of feed additives and other products in the animal health business.
- Both operating profit and ordinary profit are expected to exceed the previous year's levels thanks to the effect of increased net sales.
- Net profit for the year is estimated to be higher than the previous announcement and at the same level as last year, when extraordinary loss and extraordinary profit had an impact on net profit.

Capital Expenditures, Depreciation and Amortization, and R&D expenses


Capital Expenditures

(Tangible and software transfer basis)
(Millions of yen)




Depreciation and Amortization

(Tangible/intangible total)
(Millions of yen)



R&D expenses

(Millions of yen)




Major Factors

- Capital expenditures : Expected to exceed previous year's level due to scheduled partial renovation of Iwaki Factory.
- Depreciation and Amortization : Expected to exceed previous year's level because of impact of costs for amortization of sales rights, among others.
- R&D expenses : Despite the deferral of research expenses, these will be recorded from the third quarter onward, and are expected to exceed the previous year's level as initially projected.

Return to Shareholders/Cross-shareholdings

Changes in dividends per share



Return to shareholders

Our basic policy is to pay stable and continuous dividends to fairly return our profits to shareholders. In light of our recent situation, our annual dividends per share will be 16 yen.

Cross-shareholdings

We check whether or not it is appropriate to continue cross-shareholdings from the viewpoint of capital efficiency. We work to reduce the holding of any shares the holding of which is not considered very meaningful. We intend to pursue the goal of disposing of three issues by the end of this fiscal year.

*1 Included dividend for commemoration of 100th anniversary 3 yen

*2 Interim dividends 7 yen in FY2021 are derived from other capital surplus, and are excluded from dividend payout ratio

Overview of 2Q FY2022 Interim Annual Report



Takashi Yamaguchi,

President, Member of the Board, Representative Director

ASKA Pharmaceutical Holdings Co., Ltd.

ASKA Pharmaceutical Holdings Co., Ltd.

Interim Summary of
Fiscal Year Ending March 31, 2023

Interim Summary of 2nd Year of Medium-Term Management Plan 2025

The Medium-Term Management Plan 2025 Numerical Targets
Net sales: 70 billion yen, Operating profit rate: 8%, ROE: 8%

Second year of the medium-term management plan

2Q FY2022 Actual

Net sales: 30.1 billion yen Operating profit rate: 9.5%



Net sales Targets : 60 billion yen

Steady Progress Toward Achievement of Medium-Term Management Plan

Results of Business Companies

ASKA Pharmaceutical Co., Ltd.

- DroEthi® COMBINATION TABLETS (dysmenorrhea agent) launched solely by ASKA.
- Licensed grant exclusive rights to develop and market the oral contraceptive drug Drospirenone to a South Korean company.
- Signed a Co-promotion Agreement with Melody International Ltd. for “Fetal Monitor iCTG” in Japan.

ASKA Animal Health Co., Ltd.

- Herb-based anti-spider mixed feed “WAKUMO HATE” won the IPPS* Award 2022.
- Agreement reached on the transfer of a posterior pituitary hormone preparation “Veterinary Oxytocin Injectable Solution DSP” from Sumitomo Pharma Animal Health Co., Ltd.


ASKA Pharma Medical Co., Ltd.

- Acquired accreditation as a clinical laboratory and began accepting orders for testing from medical institutions.

Each company achieves results that lead to the next step

* International Poultry & Pig Show Japan 2022

Become a Total Healthcare Company with a Strong Foundation as a Specialty Pharma Company



Group Companies' Initiatives

ASKA Pharmaceutical Co., Ltd.

- Interim Summary of FY2022
 - Specialty Areas
 - Development Pipeline
 - Overseas Business Development

ASKA Pharmaceutical Co., Ltd.


■ Interim Summary of FY2022

- Specialty Areas
- Development Pipeline
- Overseas Business Development

Environmental Changes Related to Women's Healthcare and The Domestic Ob/Gyn Market Trend

The domestic Ob/Gyn market trend

Latest forecast by Fuji Keizai ^{*1} (billions of yen)



The market is projected to grow from **82.6 billion yen**^{*2} to **94.5 billion yen**^{*1} in 2025

Environmental Changes Related to Women

- ✓ Promotion of women's advancement
- ✓ Advancement in women's participation in society
- ✓ Social attention to medical issues



- ✓ Establishment of gynecology-specific disease treatment and management fee ^{*3}
- ✓ Promotion of femtech
- ✓ Improvement of health literacy

Stays attuned to women and aims for sustainable growth

^{*1} Source: Fuji Keizai "Trend Analysis and Future Forecasts for Obstetrics and Gynecology-Related Markets Featured in Insurance Coverage" (unauthorized reproduction prohibited)

^{*2} Source: Fuji Keizai "Ethical Drugs 2018-2019 Databook No. 4" (unauthorized reproduction prohibited)


^{*3} 2020 Medical fees revision

Becoming a Leading Company in the Field of Obstetrics and Gynecology

Ob/Gyn product sales forecasts based on in-house analysis Previous presentation materials (excerpt)



Latest forecasts based on in-house analysis



Achievement of highest sales in obstetrics and gynecology is projected to be ahead of schedule

^{*1} Image based on in-house analysis

^{*2} Source: Fuji Keizai "Trend Analysis and Future Forecasts for Obstetrics and Gynecology-Related Markets Featured in Insurance Coverage" Obstetrics and Gynecology Ethical Drug Market, 2022 Estimate (unauthorized reproduction prohibited)

Obstetrics and Gynecology Products by Life Stage

Early childhood	Puberty	Sexual maturity	Menopause	Old age		
	Oral contraception	Drospirenone (LF111)	ANGE	NORLEVO	Menopause	HOLIN
	Iron deficiency anemia	Riona (Co-Pro*)				
	Hypozincemia	NOBELZIN (Co-Pro*)				
	STD/infection	Cervical dysplasia drugs	Rapid SP Chlamydia (Co-pro*)			
	Uterine fibroids	RELUMINA	LEUPRORELIN			
	Endometriosis	Jemina (Co-Pro)	FREWELL (AG)	DroEthi		
	Dysmenorrhea	PMS/PMDD drugs	PLANOVAR			
	Menstrual disorder		Adhesion barrier			
	Miscarriage	Magsent	MAGNESOL			
	Premature birth	RITODRINE	ATONIN			
	Childbirth					
	Infertility	HMG	uFSH	SEXOVID		
		LUTEUM	GONATROPIN			

RELUMINA Tablets
Additional indication for Endometriosis (December 2021)

DroEthi Combination Tablets
Launched in June 2022

Expands the lineup and contributes to women's healthcare

Now on sale


Under development

*Mainly in the field of obstetrics and gynecology

Growth Driver - RELUMINA (relugolix)


RELUMINA sales trend

*Financial results base (millions of yen)



Estimated number of patients taking RELUMINA or LEUPRORELIN and share percentage of RELUMINA

additional Indication approved within the marketing authorization for endometriosis (December 2021)



Establishes RELUMINA's position in the endometriosis treatment


Source: Encise Inc. (unauthorized reproduction prohibited)

Further Contribution to the Treatment of Dysmenorrhea

LEP* market continues to expand

(thousands of sheets)

■ ASKA products ■ Competitors' products



DroEthi® Combination Tablets

Only ASKA launched (June 2022)

- ✓ Providing options for dysmenorrhea patients by having a lineup of three LEP* formulation
- ✓ Acquire further market share in the growing LEP formulation market

Our LEP* formulations

Jemina® tablets

FREWELL® COMBINATION TABLETS

DroEthi® COMBINATION TABLETS

Contributes to dysmenorrhea treatment

Source: Encise Inc. (unauthorized reproduction prohibited)


Notes: Jemina tablets are co-promoted with Nobelpharma Co., Ltd.

* Low-dose Estrogen/Progestin combination

Promotion of Femtech

Efforts on Femtech


Signed a 4-company consortium agreement towards solving women's health issues*



Signed a co-promotion agreement for "Fetal Monitor iCTG" with Melody International Ltd.



Ran a booth at 1st Femtech Tokyo (Oct. 20-Oct. 22)




We work to solve women's health issues through various technologies and methods in addition to ethical drugs

* Accepted as a Femtech Support Service Demonstration Project for FY2022 sponsored by METI, and signed a consortium agreement

Contributing to Unmet Medical Needs by RIFXIMA (rifaximin)

RIFXIMA sales trend

*Financial results base (millions of yen)



Solid growth projected

Clinical Practice Guidelines for Liver Cirrhosis 2020

Published in November 2020

Strength of recommendation:
Strongly recommended

Evidence level:
A

Efforts to spread the Guidelines: Utilizing digital technology in COVID-19 pandemic

- ✓ Promoting cooperation between community healthcare providers
- ✓ Providing higher-quality information

Further commitment to meet unmet medical needs
Ph II/III clinical trial for pediatric indication for hepatic encephalopathy is supposed to be terminated in November



Establishes itself as the standard treatment for hepatic encephalopathy

A Leading Company for Thyroid Treatment

Sales trend of product for the thyroid *1

*Financial results base (millions of yen)

Sustainable growth projected



■ “Efforts to raise thyroid awareness” in general public

Distributing promotional videos through the “TVer”.
Publishing articles in women's magazines.
Creating web pages for general public.

■ “Thyroid Web Seminar” for healthcare professionals

Through cooperation with
Canon Medical Systems,
specialists will give lectures to
improve diagnostic skills.



Promotes activities to raise awareness and contributes to treatments for patients

*1 THYRADIN, MERCAZOLE, PROPACIL

ASKA Pharmaceutical Co., Ltd.

■ Interim Summary of FY2022

- Specialty Areas
- Development Pipeline
- Overseas Business Development

Development Pipeline

R&D Status (as of November 2022)

 Changes from last time

Development code (generic name) Indication	Research* ¹	Non-clinical* ¹	Ph I	Ph II	Ph III	Application	Approval
LF111 (drospirenone) Contraception					Ph III Ongoing		
(Option agreement) Treatment for PMS/PMDD* ²					Investigator-initiated Ph II Ongoing		
(Option agreement) Treatment for Cervical Dysplasia					Phase I / II Ongoing in Korea		
AKP-022 (Relugolix Combination Tablet) Uterine fibroids					Preparing for clinical trials		
Theme A / Ob/Gyn							
Theme B / Ob/Gyn							
TRM-270 (adhesion barrier) (Gastroenterology and Ob/Gyn)					Ph III Ongoing		
L-105 (rifaximin) Hepatic encephalopathy (pediatrics)					Ph II/III Ongoing		
Theme C / Internal Medicine							
AKP-009 (Iudaterone acetate) Benign prostatic hyperplasia					Ph II a Completed* ³		
AKP-017 (nasal testosterone)					Preparing for clinical trials		
AKP-021 / mPGES-1 inhibitor agent							
Theme D / Urology							

*1 Details not disclosed due to research and non-clinical stage *2 Premenstrual syndrome/premenstrual dysphoric disorder

*3 The additional Ph I clinical trial conducted to confirm maximum efficacy based on the results of the Ph IIa clinical trial has been completed

Building the next core products

Relugolix Combination Tablet

Licensing agreement with Takeda Pharmaceutical Company Limited.

September 27, 2021

Summary

- ✓ Entered into a license agreement for exclusive development and commercialization for uterine fibroids in Japan.
- ✓ Combination of relugolix, estradiol-INN and norethindrone acetate-INN.
- ✓ Expected to be used for a long term treatment.
- ✓ The number of patients with uterine fibroids is estimated to be around 2 million in Japan.
- ✓ Other companies have already obtained approval in Europe and in the United States.

Proposing a new option for uterine fibroid treatment

Aims for sustainable growth

ASKA Pharmaceutical Co., Ltd.

■ Interim Summary of FY2022

- Specialty Areas
- Development Pipeline
- Overseas Business Development

Business Development in Asia

Vietnam

Equity-method affiliate

Ha Tay Pharmaceutical Joint Stock Company



Status of construction of new factory (PIC/S-GMP compliant)


(Production capacity: 2 billion tablets/year, scheduled for operation in FY2023)

- Construction ceremony was held. Our officers visited the site.
- Construction progressed as planned. Construction of structure was completed in September. From October, installation of production equipment started sequentially.



Expand personnel exchange

- Two of our employees have been seconded to Hataphar and are learning local marketing and sales methods.
- Two Hataphar employees have been accepted at our Iwaki Factory and are undergoing training program to learn production techniques.



Aims to supply international-level drugs to Vietnam and Southeast Asia


ASKA Animal Health Co., Ltd.

Domestic Veterinary Pharmaceutical Market and Net Sales Composition of ASKA Animal Health


Domestic veterinary drug market trends

in-house analysis, millions of yen

■ Companion Animal Market ■ Industrial Animal Market
 < canine and feline pharmaceuticals >



The companion animal market is projected to grow



ASKA Animal Health: Situation and Efforts

Situation and Efforts

- Sales have grown in the three core products: L-methionine (feed additive), AIVLOSIN (antimicrobial for chickens and pigs), and PRID DELTA (reproductive device for cows).
- It was agreed to transfer the marketing of Veterinary Oxytocin Injectable Solution DSP, a postpituitary hormone preparation, to ASKA Animal Health from Sumitomo Pharma Animal Health (as from November 1).
- ASKA Animal Health continues to develop new customers through running booths at large exhibitions and Web seminars.


Focused Efforts in 2nd Half

Market penetration of TRILOSTANE TABLETS “ASKA” for treatment of canine hyperadrenocorticism, scheduled for release (in November)

Features

- Easy-to-ingest tablets (new formula generic)
- Product designed for small dogs (in Japan)
- Consideration given to the product's potential effect on women by using film-coated tablets

TRILOSTANE TABLETS 2.5mg/5mg/10mg「ASKA」



Contributes to the maintenance of health of companion animals

ASKA Pharma Medical Co., Ltd.

ASKA Pharma Medical: Initiatives of Major Themes for FY2022

Hair-growth diagnostics

Initiatives to expand test items

Developed and released a kit for measuring hair hormone levels for male menopause

Thyroid disease business

Collaboration with ASKA Pharmaceutical's Sales Division

Total support for thyroid disease (testing and treatments)

Structure reinforcement

Accreditation as a Clinical Laboratory(October 1, 2022)

Began accepting orders for testing from medical institutions and strengthened cooperation with testing companies

Contributes to the creation of a vibrant, healthy society through the latest measurement technologies

Promote ESG Management

Commitment to Carbon Neutral

Objectives and efforts on CO₂ emissions volume

ASKA Pharmaceutical's target

Reduce CO₂ emissions volume
by 46% by 2030 from 2013*

CO₂ emissions volume of ASKA Pharmaceutical

FY2013
17,726t



FY2021
12,251t (30% reduction)



FY2030(goal)
9,572t

Efforts to reduce CO₂ emissions

- Introduction of cogeneration at Iwaki Factory
- Introduction of hybrid vehicles for sales activities
- Head office's switchover to LED





Projects under consideration toward further CO₂ emissions reduction

- Switchover to green energies
- Solar power installation (PPA model)
- Iwaki Factory's switchover to LED

We will work to achieve our objectives

* Scope1 and 2 emissions

Our Characteristic Material Issues

ESG	NO	Material issues	Company-wide action plan	KPIs	SDGs
S	(8)	Contribution to women's health	Total support for women's health	Expansion of product lineup for each life stage of women, i.e., puberty, reproductive age, menopause, and late life Contributions to female healthcare through provision of products Activities to raise awareness of women's health and diseases: Efforts in "Health Lab Mint+ for Women's health"	 
Activity reports		<ul style="list-style-type: none"> Launched DroEthi Combination Tablets "ASKA." Raised thyroid awareness through video distribution (TVer) (1.23 million views). Created a dysmenorrhea checklist for general public to raise disease awareness. Disseminated information on women's health through "Health Lab Mint+ for Women's health." 			
ESG	NO	Material issues	Company-wide action plan	KPIs	SDGs
S	(9)	Contribution to animal health	Contribution to creation of a society where people and animals can live together	Promotion of animal welfare Development of products useful for maintaining health of companion animals	 
Activity reports		<ul style="list-style-type: none"> Offered to livestock farmers yeast products, etc. intended to improve feed efficiency and to improve livestock health. Promoted development of therapeutic drugs for companion animals (canines and felines), among others. 			

Promotes ESG management and solves issues

**ASKA Pharmaceutical Holdings Group
Corporate Message**

For a Healthy Tomorrow and Future.




ASKA Pharmaceutical Holdings Co., Ltd.

Appendix

Sales Ratio by Area and Sales Proportion of Brand-name Drugs


Sales Ratio by Area(2Q FY2022)



- Obstetrics and Gynecology
- Internal medicine (Gastroenterology and thyroid)
- Urology
- Others

Sales Proportion of Brand-name Drugs

- Brand-name drugs
- Generic drugs



Aims to increase the ratio of brand-name drugs
(Numerical target in The Medium-Term
Management Plan 2025 : 70%)

Increase in the Number of Menstrual Cycles due to Changes in Life Events


Women today experience their first menstruation earlier, tend to marry later, and experience fewer childbirths than women in past generations. The increase in the number of menstrual cycles (MCs) experienced in women's lifetime is considered a factor for the increase in dysmenorrhea and other menstrual problems.

Number of MCs experienced by women today

Number of lifetime MCs: **Approx. 450**

Number of lifetime childbirths: **Approx. 2**

Menstrual periods of women today




Number of MCs experienced by women in past generations

Number of lifetime MCs: **Approx. 50**


Number of lifetime childbirths: **Approx. 5**

Menstrual periods of women in past generations




Number of Uterine fibroids/Endometriosis/Dysmenorrhea Patients


(Extended estimates from electronic receipt data, 12 months from July of each year to June of the following year)



Uterine fibroids



Endometriosis



Dysmenorrhea

Insurance Coverage of ASKA Pharmaceutical drugs for the Indication of Infertility Treatment

From April 2022, infertility treatments have been covered by insurance, and the following drugs are now covered by insurance and listed on the NHI drug price list for infertility treatment

Newly insured products in the NHI drug price

PLANOVAR® TABLETS

uFSH INJECTION

HMG INTRAMUSCULAR INJECTION

GONATROPIN® FOR INJECTION

GONATROPIN® FOR INTRAMUSCULAR INJECTION

**Patients have been
increasing since insurance
coverage**

Newly listed product in the NHI drug price

LUTEUM® VAGINAL SUPPOSITORIES

**Meeting medical needs
in the area of infertility
treatment**

RIFXIMA: Efforts to Spread the Guidelines

Efforts to spread the Guidelines:
Digital strategies in COVID-19
pandemic

Area Webinar plans

0 plan
FY2020 1st half

➔

41 plans
FY2022 1st half


Number of interviews with doctors
by head office's dedicated division

36 interviews
FY2020 1st half

➔

325 interviews
FY2022 1st half

Awareness of and experience in treating
covert hepatic encephalopathy*



82 doctors who specialize in
hepatic cirrhosis treatment
(August 2022 survey)


- Know disease name and have treatment experience
- Know disease name but have no treatment experience
- Don't know

**Contribution to hepatic encephalopathy
patients through spreading
the Guidelines**

* Hepatic encephalopathy with few clinical symptoms. Some cases may transition to overt hepatic encephalopathy.

About Thyroid Glands


Thyroid awareness



"Thyroid Awareness Survey" by ASKA Pharmaceutical, March 2022. Survey respondents: 1,000 men and women (500 each) in their 20s, 30s, and 40s from across Japan.

Roles of thyroid

The thyroid is located just under the Adam's apple and looks like a butterfly. The thyroid produces "thyroid hormone," which is very important for humans to live. Thyroid hormone promotes metabolism, regulates pulse rate, body temperature, the functions of autonomic nerves, etc., and maintains constant energy consumption.



Excessive thyroid hormone results in ...

"hyperthyroidism," a disease in which excessive production of thyroid hormone causes excessive metabolism.

Deficient thyroid hormone results in ...

"hypothyroidism," a disease in which reduced production of thyroid hormone causes low metabolism.

TOPIC

Thyroid diseases are characteristically **mistaken for other diseases** because of their varied symptoms.

- Diseases which thyroid diseases are often mistaken for include:**
- Menopausal disorder
 - Dementia
 - Heart disease
 - Autonomic imbalance, depression
 - Aging
 - AGA

About Hataphar

Company name : Ha Tay Pharmaceutical Joint Stock Company

Founded : 1965

Head office: Hanoi, Vietnam

Number of employees : Approx. 1000

Listed stock exchanges : Hanoi Securities Trading Center (2008)

Net sales: 2,006,475 million VND (2020)

Net profit: 96,109 million VND (2020)



- Businesses: Manufacturing, sales and importation of pharmaceuticals, nonprescription and nutraceutical products
- Second largest pharmaceutical company in Vietnam in terms of net sales in 2019
- Branch offices and others in major cities, with distribution and sales covering nationwide in Vietnam

Promotion of Women's Advancement

We implement personnel measures by pursuing such efforts as creating a work environment that allows each employee to take maximum advantage of his/her characteristics and skills, and providing training. We strongly promote women's advancement, as we particularly acknowledge that active female participation will lead to our further growth, as we operate under the slogan of "Contribution to women's health."

Relevant data*

Percentage of female employees in managerial positions

5.1% in 2017 → **8.1%** in June 2022 → **15%** goal for 2025

Percentage of female full-time employees

24.9% in 2017 → **28.9%** in 2021 → **35%** goal for 2025

Percentage of female candidates for managerial positions

15.3% in 2017 → **23.7%** in 2021 → **30%** goal for 2025

Male childcare leave utilization rate

45.8% in 2017 → **80.0% (estimate)** in 2021 → **100%** goal for 2025

We promote the creation of an environment where women will shine

* As of the end of each relevant fiscal year, on a non-consolidated basis of ASKA Pharmaceutical.

For details, see the website of ASKA Pharmaceutical Holdings: https://www.aska-pharma-hd.co.jp/csr/social/labor_practices.html#anc6

(Japanese version only)



Activities of Health Lab Mint+ for Women's health



■ Held an online seminar

Mint+ × ABC HEALTH LABO

- a Project to Promote Women's Health Starting from Food -

[Theme] "What we want women to know! Not well-known facts about the thyroid"


<Lecture 1> "What we want women to know! Facts about the thyroid" by Dr. Ai Yoshihara, Medical Director of Internal Medicine, Ito Hospital

<Lecture 2> "Self-care starting with meals" by registered dietitian

<Demo lesson> Chili sauce salmon

■ Conducted the online survey

Released the result of the "Survey of Teenage Men and Women on Menstruation and Other Painful Conditions Specific to Women"



■ Participated at "1st Femtech Tokyo"

ASKA Pharmaceutical Co., Ltd.

ASKA Pharmamedical Co., Ltd.

Introduction of Mint+'s activities

Testing technologies of ASKA Pharma Medical



Key message

Knowing yourself, is protecting yourself

Inquiries

Corporate Planning Department

Tel : +81-3-5484-8366

e-mail : kouhou@aska-pharma.co.jp